Cette année, la Société offre un vote contraignant sur la politique de rémunération 2017 de son Directeur Général pour la première fois et dans le cadre de la nouvelle loi "Sapin II" (résolution 14).
Proxinvest recommande aux actionnaires de s’opposer à cette résolution étant donné que la Société ne communique pas la politique de rémunération de son dirigeant pour l’exercice, ni les montants qui y sont attachés.
En ce qui concerne les autorisations d'augmentation du capital, la Société ne suspend toujours pas ces opérations en période d'offre publique. Ces résolutions peuvent donc être assimilées à des dispositifs anti-OPA et de ce fait, vont à l'encontre de notre politique de vote. De plus, la résolution 20 propose d’offrir un décoté de 15% les nouveaux entrants au capital, ce qui viendrait diluer de manière excessive les actionnairs.
Proxinvest recommande donc aux actionnaires de ne pas approuver la majorité de ces autorisations.
ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Summary Abivax SA (Abivax) is a biotechnology company that develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce functional cure in HIV-patients and inflammatory bowel diseases caused by a dysregulated immune response to host intestinal microflora. Abivax’s ABX544 focuses on the production and purification of neutralizing antibodies from immunized animals with specific antigen for the treatment for EBOLA virus...
In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. On November 1, 2018, the Company announced that Mr. L.S. Rasmussen will resign from his position as CEO to become the new Chairman of the board of directors as of this AGM. Mr. Rasmussen will be succeeded by Executive Vice President - Mr. Kristian Villumsen - as of the same date. Under ITEM 5.1, it is proposed to re-appoint Mr. N.P. Louis Hansen as Vice Chairman of the board of directors. Although ECGS has no (major) concerns over the re-appointment...
Item 2: Approve the Remuneration Report The structure is weighted more towards rewarding long-term performance. While there are concerns that the bonus performance metrics may not be sufficiently challenging, due to the high payout, the incentive pay is not much above guidelines.Item 3: Approve the Remuneration Policy The changes proposed to the Remuneration Policy make minor improvements to the policy. In addition, the structure of remuneration is considered acceptable, though we continue to be concerned that accelerated vesting is possible.Item 4: Approve the dividend If approved, the Com...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.